AzTrials
AzTrials

CataractNCT06528678

Patients Outcomes of a Monofocal Intraocular Lens Designed for Monovision

An observational study of Cataract, run by Clinica Baviera at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The rationale for this observational study of a CE-marked lens is to prospectively assess the performance, safety, and patient satisfaction in a group of subjects undergoing cataract surgery with bilateral implantation of the RayOne EMV in a monovision configuration. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Cataract
What is being tested?
Intraocular lens
Type of treatment
Medical device
How many people
51 participants
Where
1 siteSpain
Study dates
30 Apr 2021to 24 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who underwent cataract surgery at Clinica Baviera and implanted bilaterally with advanced monofocal intraocular lenses (RayOne EMV) with monovision configuration. The study population will comprise men and women aged 21 years or older and with an preoperative corneal astigmatism < 1.50 D.

Who may be able to join

  • Signed informed consent
  • Availability to complete follow-up examinations up to 6 months after surgery
  • Cataract for which removal by phacoemulsification and subsequent IOL implantation was planned
  • CDVA was expected to be better than 20/30 (+0.18 logMAR) after IOL implantation
  • IOL power calculated in the range of +10.0 to +30.0 D
  • Corneal astigmatism < 1.50 D
  • Candidate for refractive surgery in monovision configuration

Who cannot join

  • Women who were pregnant, nursing or planning to become pregnant during the study
  • Difficulty for cooperation
  • Inability to provide informed consent
  • Concurrent participation in another investigational drug or device
  • History of ocular trauma
  • Previous intraocular or corneal surgery
Show all 11Show fewer
  • Presence of ocular pathologies
  • Subjects with diagnosed degenerative visual disorders that were predicted to cause future acuity losses to a level of 20/30 or worse
  • Subjects who may be expected to require retinal laser treatment
  • Other eye condition that in the opinion of the investigator prevents the subject's participation in the study.
  • Any other condition that may be contraindicated according to the IOL Instructions for Use.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Clinica Baviera

    Valencia, 46004

Other trials in Spain

About this study

Official title: Visual Outcomes and Patient Satisfaction Results After Implantation of a Monofocal Intraocular Lens Designed for Monovision

The rationale for this observational study of a CE-marked lens is to prospectively assess the performance, safety, and patient satisfaction in a group of subjects undergoing cataract surgery with bilateral implantation of the RayOne EMV in a monovision configuration. In order to increase the evidence collected from real-world clinical data we are running a multicentre clinical study in several clinics of the Baviera Ophthalmological Group.

Study design: prospective, observational, non-comparative.

Conditions
Cataract
Being tested
Intraocular lens
Keywords
IOL, Monovision, Patient satisfaction
Medical subject headings
Cataract, Patient Satisfaction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intraocular lensDevice

    Lens exchange with an intraocular lens

Study groups in NCT06528678
Study groupRoleWhat they receive
EMV monovisionCataract surgery with EMV IOL
Receives: Device: Intraocular lens

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual acuity

    Visual acuity was measured using standard clinical charts

    Measured: One month postoperative

  2. Defocus curve

    Defocus curve was measured using standard clinical charts

    Measured: One month postoperative

  3. Patient Satisfaction

    Patient satisfaction was measured using the Cataract Assessment Patient Questionnaire 9 Short Form (Catquest 9SF) from 1 to 5, being 1 major difficulties and 5 cannot decide

    Measured: One month postoperative

Secondary outcomes (2)
  1. Safety of the device

    Safety of the device was measured in terms of the frequency of adverse events related to the device

    Measured: Surgery, first follow-up visit (1-month) and second follow-up visit (6-months)

  2. Quality of vision

    Quality of vision was measured using a self-administered questionnaire developed at Clinica Baviera to assess patient satisfaction regarding night vision, from 1 to 4 being 1 the maximun score and 4 the worst score

    Measured: One month postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jul 2024
  2. Study start30 Apr 2021
  3. Primary completion12 Jun 2023
  4. Study completion24 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
51 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06528678
Sponsor's protocol ID
LIO_EMV21
Status last verified
Jul 2024
First submitted
22 Jul 2024
Last updated
30 Jul 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Llovet-Rausell A, Navalon-Tortosa J, Druchkiv V, Coloma-Bockos J, Moya-Roca J, Llovet-Osuna F. Patient satisfaction and quality of vision after bilateral implantation of enhanced monofocal IOL and mini-monovision: a prospective study. Eye Vis (Lond). 2025 Jun 16;12(1):23. doi: 10.1186/s40662-025-00439-z.

    PubMed 40524216

Questions about this trial

What is this clinical trial studying?

An observational study of Cataract, run by Clinica Baviera at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual acuity (time frame: One month postoperative). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06528678, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in